<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184339</url>
  </required_header>
  <id_info>
    <org_study_id>MP2009-B</org_study_id>
    <nct_id>NCT01184339</nct_id>
  </id_info>
  <brief_title>Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives</brief_title>
  <official_title>Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPhage, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroPhage, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and
      methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's
      bacteriophage-based diagnostic platform, two gold-standard reference methods, and two
      predicate devices with similar indications for use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, FDA clinical study designed to investigate the safety and performance
      of the MicroPhage S. aureus/MSSA/MRSA test direct from blood culture positives. Informed
      consent is not anticipated, as this is a laboratory performance study with no patient
      intervention. The MicroPhage Test will be compared to site standards of care,
      market-available rapid tests, two predicate tests, and two disk diffusion tests for
      antimicrobial susceptibility. The study will last approximately 4-6 months (Bactec),
      dependent on the accrual rate of each institution.

      This study is designed to support the following product indications for use:

      The MicroPhage S. aureus/MSSA/MRSA Blood Culture Test is a qualitative in vitro diagnostic
      test for the rapid identification of Staphylococcus aureus and determination of methicillin
      susceptibility (MSSA) or methicillin resistance (MRSA) directly from positive blood cultures.

      The test uses bacteriophage amplification to rapidly and phenotypically identify the presence
      of S. aureus and assess the response of the target organism to cefoxitin as an analog to
      methicillin.

      This test is performed on positive blood cultures.

      Subculturing of positive blood cultures is necessary for further susceptibility test
      determinations.

      Results of the study analysis will be in the form of descriptive statistics (mean, median,
      standard deviation, frequencies) for all study variables. Associations among variables will
      be presented using correlation coefficients, as well as odds ratios and parameter estimates
      from multivariable regression (linear and logistic) where applicable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the performance of the MicroPhage S. aureus/ MSSA/MRSA Test for identification of S. aureus and determination of MRSA and MSSA direct from clinical blood culture positives against gold standard laboratory tests.</measure>
    <time_frame>Daily per device protocol</time_frame>
    <description>i) Comparison of the MicroPhage S. aureus/MSSA/MRSA test for identification of S. aureus to the gold Standard for S. aureus (coagulase positive, catalase positive, Staphaurex positive, and PYR negative).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of comparative performance of the MicroPhage S. aureus/MRSA/MSSA Test to the Oxoid PBP2a for determination of MRSA.</measure>
    <time_frame>Daily per device protocol</time_frame>
    <description>Performance comparison of the two tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the performance of the MicroPhage S. aureus/ MSSA/MRSA Test for identification of S. aureus and determination of MRSA and MSSA direct from clinical blood culture positives against gold standard laboratory tests.</measure>
    <time_frame>Daily per device protocol</time_frame>
    <description>ii) Comparison of the MicroPhage S. aureus/MSSA/MRSA test for identification of S. aureus and determination of MRSA to the gold Standard for MRSA (S. aureus gold standard and &lt;/=10mm OXA DD or &lt;/=21mm CFX DD) iii) Comparison of the MicroPhage S. aureus/MSSA/MRSA test for identification of S. aureus and determination of MSSA to the gold Standard for MSSA (S. aureus gold standard and &gt;/=13mm OXA DD or &gt;/=22mm CFX DD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of clinical performance of the MicroPhage S. aureus/MSSA/MRSA Test to monitor S. aureus/MSSA/MRSA bacteremia clinical blood culture positives with unique subjects.</measure>
    <time_frame>Daily per device protocol</time_frame>
    <description>Study of MicroPhage Test performance to primary endpoint criteria with one sample per unique subject.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1165</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Current practice methods for the determination of bacteremia, specific to site practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold Standard ID/AST</arm_group_label>
    <description>Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).
Determination of MRSA:S. aureus gold standard and &lt;/=11mm OXA DD or &lt;/=21mm CFX DD.
Determination of MSSA: S. aureus gold standard and &gt;/=13mm OXA DD or &gt;/=22mm CFX DD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MicroPhage S. aureus/MSSA/MRSA Blood Culture Test</intervention_name>
    <description>In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.
Approximately 5 hour rapid test.</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_label>Gold Standard ID/AST</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Approximately 100 uL of deidentified blood culture sample per test sample run.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients with at least one positive blood culture.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blood culture positive samples from subjects aged 18+, with any of the following
             bottle types:

          -  BD Bactec Standard Aerobic and Anaerobic,

          -  BD Bactec Plus Aerobic and Anaerobic,

          -  Completion of the MicroPhage test protocol on the sample.

        Exclusion Criteria:

          -  Samples from subjects under 18 years of age,

          -  Samples from any other not included bottle types,

          -  Samples from blood culture positives over 24 hours from alarm,

          -  Samples deemed contaminated,

          -  Mislabeled / misidentified samples or data without documented corrections,

          -  Violations and/or deviations from the MicroPhage test protocol and/or other included
             test protocols under study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kirn, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao Qi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barth Reller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Connie Savor-Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health</affiliation>
  </overall_official>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2010</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Drew Smith, Ph.D.</name_title>
    <organization>MicroPhage, Inc.</organization>
  </responsible_party>
  <keyword>Staphylococcus</keyword>
  <keyword>aureus</keyword>
  <keyword>methicillin</keyword>
  <keyword>resistant</keyword>
  <keyword>MRSA</keyword>
  <keyword>MSSA</keyword>
  <keyword>Blood Culture</keyword>
  <keyword>diagnostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

